Approval of FOSRENOL in Germany Triggers U.S.$3 Million Payment to AnorMED (T-Net British Columbia)
Vancouver, BC, September 18, 2006--(T-Net)--AnorMED (NASDAQ:ANOR; TSX:AOM) today announced that under the terms of an existing agreement, AnorMED will receive a U.S.$3 million milestone payment from Shire Pharmaceuticals Group, plc based on the recent licensing approval received in Germany by Shire to sell FOSRENOL as a treatment for high phosphate levels in the blood, which occurs in patients

Once-Yearly Reclast(R) Demonstrates Highly Significant Fracture Risk Reductions In The Treatment Of Postmenopausal (Medical News Today)
New Phase III data presented forthe first time demonstrated that the investigational treatment Reclast(R)^(zoledronic acid) 5 mg was highly effective in reducing the incidence ofbone fracture in women with postmenopausal osteoporosis across the mostcommon fracture sites -- hip, spine and non-spine^^ -- with sustainedeffect over three years. [click link for full article]